Late gadolinium enhancement in cardiac transplant patients is associated with adverse ventricular functional parameters and clinical outcomes

Canadian Journal of Cardiology

Volumn 29, Issue 9, 2013, Pages 1076-1083

  Butler, Craig R ^a   Kumar, Andreas ^b   Toma, Mustafa ^c   Thompson, Richard ^d   Chow, Kelvin ^d   Isaac, Debra ^b   Kim, Daniel ^a   Haykowsky, Mark ^d   Friedrich, Matthias G ^e   Paterson, Ian ^a  

^a MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; GRAFT RECIPIENT; HEART DEATH; HEART GRAFT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; MALE; OUTCOME ASSESSMENT;

ADULT; AGED; CONTRAST MEDIA; DEATH; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HEART TRANSPLANTATION; HOSPITALIZATION; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84882928688     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.10.021     Document Type: Article

References (36)

1. Ingkanisorn W.P., Rhoads K.L., Aletras A.H., Kellman P., Arai A.E. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. JAm Coll Cardiol 2004, 43:2253-2259.
2. Kwong R.Y., Chan A.K., Brown K.A., et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006, 113:2733-2743.
3. Kwong R.Y., Sattar H., Wu H., et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008, 118:1011-1020.
4. Wu K.C., Weiss R.G., Thiemann D.R., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. JAm Coll Cardiol 2008, 51:2414-2421.
5. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999, 100:1992-2002.
6. Rehwald W.G., Fieno D.S., Chen E.L., Kim R.J., Judd R.M. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002, 105:224-229.
7. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. NEngl J Med 2000, 343:1445-1453.
8. Wu E., Judd R.M., Vargas J.D., Klocke F.J., Bonow R.O., Kim R.J. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001, 357:21-28.
9. Moon J.C., Sheppard M., Reed E., Lee P., Elliott P.M., Pennell D.J. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with anderson-fabry disease. JCardiovasc Magn Reson 2006, 8:479-482.
10. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. JAm Coll Cardiol 2004, 43:2260-2264.
11. Abdel-Aty H., Boye P., Zagrosek A., et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. JAm Coll Cardiol 2005, 45:1815-1822.
12. Gao S.Z., Schroeder J.S., Hunt S.A., Billingham M.E., Valantine H.A., Stinson E.B. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol 1989, 64:1093-1097.
13. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. JHeart Lung Transplant 2005, 24:1710-1720.
14. Bondarenko O., Beek A.M., Hofman M.B., et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. JCardiovasc Magn Reson 2005, 7:481-485.
15. StataCorp Stata statistical software 2003, Stata Corp, College Station, TX.
16. Steen H., Merten C., Refle S., et al. Prevalence of different gadolinium enhancement patterns in patients after heart transplantation. JAm Coll Cardiol 2008, 52:1160-1167.
17. Friedrich M.G., Sechtem U., Schulz-Menger J., et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. JAm Coll Cardiol 2009, 53:1475-1487.
18. Bruder O., Wagner A., Jensen C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 56:875-887.
19. Heidary S., Patel H., Chung J., et al. Quantitative tissue characterization of infarct core and border zone in patients with ischemic cardiomyopathy by magnetic resonance is associated with future cardiovascular events. JAm Coll Cardiol 2010, 55:2762-2768.
20. Cheong B.Y., Muthupillai R., Wilson J.M., et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation 2009, 120:2069-2076.
21. Mark P.B., Johnston N., Groenning B.A., et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006, 69:1839-1845.
22. Fliss H., Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996, 79:949-956.
23. Lund G., Morin R.L., Olivari M.T., Ring W.S. Serial myocardial T2 relaxation time measurements in normal subjects and heart transplant recipients. JHeart Transplant 1988, 7:274-279.
24. Smart F.W., Young J.B., Weilbaecher D., Kleiman N.S., Wendt R.E., Johnston D.L. Magnetic resonance imaging for assessment of tissue rejection after heterotopic heart transplantation. JHeart Lung Transplant 1993, 12:403-410.
25. Cho J.R., Park S., Choi B.W., et al. Delayed enhancement magnetic resonance imaging is a significant prognostic factor in patients with non-ischemic cardiomyopathy. Circ J 2010, 74:476-483.
26. Assomull R.G., Prasad S.K., Lyne J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. JAm Coll Cardiol 2006, 48:1977-1985.
27. Adabag A.S., Maron B.J., Appelbaum E., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. JAm Coll Cardiol 2008, 51:1369-1374.
28. Bogun F.M., Desjardins B., Good E., et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. JAm Coll Cardiol 2009, 53:1138-1145.
29. Desjardins B., Crawford T., Good E., et al. Infarct architecture and characteristics on delayed enhanced magnetic resonance imaging and electroanatomic mapping in patients with postinfarction ventricular arrhythmia. Heart Rhythm 2009, 6:644-651.
30. Schmidt A., Azevedo C.F., Cheng A., et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 2007, 115:2006-2014.
31. Labarrere C.A., Nelson D.R., Cox C.J., Pitts D., Kirlin P., Halbrook H. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 2000, 284:457-464.
32. Yamani M.H., Haji S.A., Starling R.C., et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. JAm Coll Cardiol 2002, 39:970-977.
33. Gerdts E., Wachtell K., Omvik P., et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension 2007, 49:311-316.
34. Modell B., Khan M., Darlison M., Westwood M.A., Ingram D., Pennell D.J. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. JCardiovasc Magn Reson 2008, 10:42.
35. Butler C.R., Thompson R., Haykowsky M., Toma M., Paterson I. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. JCardiovasc Magn Reson 2009, 11:7.
36. Iles L., Pfluger H., Phrommintikul A., et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. JAm Coll Cardiol 2008, 52:1574-1580.